nodes	percent_of_prediction	percent_of_DWPC	metapath
Mianserin—CYP2B6—Ifosfamide—testicular cancer	0.133	0.31	CbGbCtD
Mianserin—CYP2B6—Cisplatin—testicular cancer	0.0649	0.151	CbGbCtD
Mianserin—HTR7—vas deferens—testicular cancer	0.049	0.364	CbGeAlD
Mianserin—CYP2B6—Doxorubicin—testicular cancer	0.0435	0.101	CbGbCtD
Mianserin—CYP3A4—Ifosfamide—testicular cancer	0.041	0.0953	CbGbCtD
Mianserin—CYP1A2—Etoposide—testicular cancer	0.0374	0.0869	CbGbCtD
Mianserin—CYP2D6—Vinblastine—testicular cancer	0.0342	0.0795	CbGbCtD
Mianserin—CYP3A4—Vinblastine—testicular cancer	0.0217	0.0505	CbGbCtD
Mianserin—CYP2D6—Doxorubicin—testicular cancer	0.021	0.0488	CbGbCtD
Mianserin—HTR7—vein—testicular cancer	0.0208	0.155	CbGeAlD
Mianserin—CYP3A4—Etoposide—testicular cancer	0.0196	0.0455	CbGbCtD
Mianserin—CYP3A4—Doxorubicin—testicular cancer	0.0134	0.0311	CbGbCtD
Mianserin—HTR2A—vein—testicular cancer	0.013	0.0964	CbGeAlD
Mianserin—ADRA2C—seminal vesicle—testicular cancer	0.0034	0.0252	CbGeAlD
Mianserin—SLC6A2—gonad—testicular cancer	0.00278	0.0206	CbGeAlD
Mianserin—HRH2—lymph node—testicular cancer	0.00275	0.0204	CbGeAlD
Mianserin—ADRA2A—seminal vesicle—testicular cancer	0.00272	0.0201	CbGeAlD
Mianserin—HTR7—gonad—testicular cancer	0.00268	0.0199	CbGeAlD
Mianserin—SLC6A3—testis—testicular cancer	0.00248	0.0184	CbGeAlD
Mianserin—HTR2A—embryo—testicular cancer	0.00246	0.0182	CbGeAlD
Mianserin—CYP2B6—gonad—testicular cancer	0.00205	0.0152	CbGeAlD
Mianserin—SLC6A2—testis—testicular cancer	0.002	0.0148	CbGeAlD
Mianserin—ADRA2C—female gonad—testicular cancer	0.002	0.0148	CbGeAlD
Mianserin—ADRA2A—gonad—testicular cancer	0.00196	0.0146	CbGeAlD
Mianserin—HTR7—testis—testicular cancer	0.00193	0.0143	CbGeAlD
Mianserin—DRD2—testis—testicular cancer	0.00182	0.0135	CbGeAlD
Mianserin—ADRA2C—testis—testicular cancer	0.00177	0.0132	CbGeAlD
Mianserin—HTR2A—gonad—testicular cancer	0.00167	0.0124	CbGeAlD
Mianserin—Thrombocytopenia—Bleomycin—testicular cancer	0.00165	0.0041	CcSEcCtD
Mianserin—Feeling abnormal—Vinblastine—testicular cancer	0.00165	0.00409	CcSEcCtD
Mianserin—Myalgia—Dactinomycin—testicular cancer	0.00164	0.00408	CcSEcCtD
Mianserin—Eye disorder—Cisplatin—testicular cancer	0.00164	0.00406	CcSEcCtD
Mianserin—Anaemia—Ifosfamide—testicular cancer	0.00164	0.00406	CcSEcCtD
Mianserin—Tinnitus—Cisplatin—testicular cancer	0.00163	0.00405	CcSEcCtD
Mianserin—HTR2B—lymph node—testicular cancer	0.00163	0.0121	CbGeAlD
Mianserin—Cardiac disorder—Cisplatin—testicular cancer	0.00163	0.00403	CcSEcCtD
Mianserin—Agitation—Ifosfamide—testicular cancer	0.00163	0.00403	CcSEcCtD
Mianserin—HRH1—female gonad—testicular cancer	0.00162	0.012	CbGeAlD
Mianserin—ADRA2A—female gonad—testicular cancer	0.0016	0.0118	CbGeAlD
Mianserin—Vertigo—Ifosfamide—testicular cancer	0.00159	0.00394	CcSEcCtD
Mianserin—Leukopenia—Ifosfamide—testicular cancer	0.00158	0.00393	CcSEcCtD
Mianserin—Mediastinal disorder—Cisplatin—testicular cancer	0.00158	0.00392	CcSEcCtD
Mianserin—Hypotension—Bleomycin—testicular cancer	0.00158	0.00392	CcSEcCtD
Mianserin—Oedema—Dactinomycin—testicular cancer	0.00158	0.00391	CcSEcCtD
Mianserin—Asthenia—Chlorambucil—testicular cancer	0.00157	0.00388	CcSEcCtD
Mianserin—Pruritus—Chlorambucil—testicular cancer	0.00154	0.00383	CcSEcCtD
Mianserin—Thrombocytopenia—Dactinomycin—testicular cancer	0.00154	0.00383	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Bleomycin—testicular cancer	0.00154	0.00382	CcSEcCtD
Mianserin—Convulsion—Ifosfamide—testicular cancer	0.00153	0.0038	CcSEcCtD
Mianserin—Hypertension—Ifosfamide—testicular cancer	0.00153	0.00379	CcSEcCtD
Mianserin—Paraesthesia—Bleomycin—testicular cancer	0.00152	0.00376	CcSEcCtD
Mianserin—Arthralgia—Ifosfamide—testicular cancer	0.00151	0.00374	CcSEcCtD
Mianserin—Myalgia—Ifosfamide—testicular cancer	0.00151	0.00374	CcSEcCtD
Mianserin—Eye disorder—Etoposide—testicular cancer	0.0015	0.00372	CcSEcCtD
Mianserin—Unspecified disorder of skin and subcutaneous tissue—Ifosfamide—testicular cancer	0.0015	0.00371	CcSEcCtD
Mianserin—Cardiac disorder—Etoposide—testicular cancer	0.00149	0.00369	CcSEcCtD
Mianserin—Hepatic function abnormal—Epirubicin—testicular cancer	0.00149	0.00369	CcSEcCtD
Mianserin—CYP2B6—testis—testicular cancer	0.00147	0.0109	CbGeAlD
Mianserin—Angiopathy—Etoposide—testicular cancer	0.00146	0.00361	CcSEcCtD
Mianserin—Confusional state—Ifosfamide—testicular cancer	0.00146	0.00361	CcSEcCtD
Mianserin—SLC6A2—lymph node—testicular cancer	0.00145	0.0108	CbGeAlD
Mianserin—Mediastinal disorder—Etoposide—testicular cancer	0.00145	0.00359	CcSEcCtD
Mianserin—Oedema—Ifosfamide—testicular cancer	0.00144	0.00358	CcSEcCtD
Mianserin—HRH1—testis—testicular cancer	0.00144	0.0107	CbGeAlD
Mianserin—Musculoskeletal discomfort—Dactinomycin—testicular cancer	0.00144	0.00356	CcSEcCtD
Mianserin—Asthenia—Vinblastine—testicular cancer	0.00144	0.00356	CcSEcCtD
Mianserin—Tremor—Cisplatin—testicular cancer	0.00143	0.00354	CcSEcCtD
Mianserin—Lethargy—Methotrexate—testicular cancer	0.00142	0.00352	CcSEcCtD
Mianserin—Nervous system disorder—Ifosfamide—testicular cancer	0.00142	0.00351	CcSEcCtD
Mianserin—ADRA2A—testis—testicular cancer	0.00141	0.0105	CbGeAlD
Mianserin—Thrombocytopenia—Ifosfamide—testicular cancer	0.00141	0.00351	CcSEcCtD
Mianserin—Anaemia—Cisplatin—testicular cancer	0.00141	0.0035	CcSEcCtD
Mianserin—Skin disorder—Ifosfamide—testicular cancer	0.0014	0.00348	CcSEcCtD
Mianserin—Feeling abnormal—Bleomycin—testicular cancer	0.00139	0.00345	CcSEcCtD
Mianserin—Hepatic function abnormal—Doxorubicin—testicular cancer	0.00138	0.00342	CcSEcCtD
Mianserin—Leukopenia—Cisplatin—testicular cancer	0.00137	0.00339	CcSEcCtD
Mianserin—Fatigue—Dactinomycin—testicular cancer	0.00136	0.00337	CcSEcCtD
Mianserin—Hypotension—Ifosfamide—testicular cancer	0.00135	0.00335	CcSEcCtD
Mianserin—Cardiac failure—Epirubicin—testicular cancer	0.00133	0.00331	CcSEcCtD
Mianserin—Lethargy—Epirubicin—testicular cancer	0.00133	0.00329	CcSEcCtD
Mianserin—Dizziness—Vinblastine—testicular cancer	0.00132	0.00328	CcSEcCtD
Mianserin—Convulsion—Cisplatin—testicular cancer	0.00132	0.00328	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Ifosfamide—testicular cancer	0.00132	0.00326	CcSEcCtD
Mianserin—Diplopia—Epirubicin—testicular cancer	0.0013	0.00323	CcSEcCtD
Mianserin—Myalgia—Cisplatin—testicular cancer	0.0013	0.00322	CcSEcCtD
Mianserin—Feeling abnormal—Dactinomycin—testicular cancer	0.0013	0.00322	CcSEcCtD
Mianserin—Paraesthesia—Ifosfamide—testicular cancer	0.0013	0.00322	CcSEcCtD
Mianserin—Anaemia—Etoposide—testicular cancer	0.00129	0.0032	CcSEcCtD
Mianserin—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—testicular cancer	0.00129	0.0032	CcSEcCtD
Mianserin—ADRA2C—lymph node—testicular cancer	0.00129	0.00953	CbGeAlD
Mianserin—Somnolence—Ifosfamide—testicular cancer	0.00128	0.00318	CcSEcCtD
Mianserin—Breast disorder—Methotrexate—testicular cancer	0.00126	0.00311	CcSEcCtD
Mianserin—Vertigo—Etoposide—testicular cancer	0.00126	0.00311	CcSEcCtD
Mianserin—Headache—Vinblastine—testicular cancer	0.00125	0.00311	CcSEcCtD
Mianserin—Leukopenia—Etoposide—testicular cancer	0.00125	0.0031	CcSEcCtD
Mianserin—Gastrointestinal disorder—Ifosfamide—testicular cancer	0.00125	0.00309	CcSEcCtD
Mianserin—Fatigue—Ifosfamide—testicular cancer	0.00124	0.00309	CcSEcCtD
Mianserin—Oedema—Cisplatin—testicular cancer	0.00124	0.00309	CcSEcCtD
Mianserin—Cardiac arrest—Epirubicin—testicular cancer	0.00124	0.00307	CcSEcCtD
Mianserin—CYP2D6—female gonad—testicular cancer	0.00124	0.00916	CbGeAlD
Mianserin—Constipation—Ifosfamide—testicular cancer	0.00123	0.00306	CcSEcCtD
Mianserin—Cardiac failure—Doxorubicin—testicular cancer	0.00123	0.00306	CcSEcCtD
Mianserin—Loss of consciousness—Etoposide—testicular cancer	0.00123	0.00305	CcSEcCtD
Mianserin—Lethargy—Doxorubicin—testicular cancer	0.00123	0.00305	CcSEcCtD
Mianserin—Nervous system disorder—Cisplatin—testicular cancer	0.00122	0.00303	CcSEcCtD
Mianserin—Thrombocytopenia—Cisplatin—testicular cancer	0.00122	0.00302	CcSEcCtD
Mianserin—Tachycardia—Cisplatin—testicular cancer	0.00121	0.00301	CcSEcCtD
Mianserin—Asthenia—Bleomycin—testicular cancer	0.00121	0.00301	CcSEcCtD
Mianserin—Convulsion—Etoposide—testicular cancer	0.00121	0.003	CcSEcCtD
Mianserin—Skin disorder—Cisplatin—testicular cancer	0.00121	0.003	CcSEcCtD
Mianserin—Hypertension—Etoposide—testicular cancer	0.00121	0.00299	CcSEcCtD
Mianserin—Diplopia—Doxorubicin—testicular cancer	0.0012	0.00298	CcSEcCtD
Mianserin—HTR2A—testis—testicular cancer	0.0012	0.00892	CbGeAlD
Mianserin—Pruritus—Bleomycin—testicular cancer	0.0012	0.00296	CcSEcCtD
Mianserin—Feeling abnormal—Ifosfamide—testicular cancer	0.00119	0.00295	CcSEcCtD
Mianserin—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	0.00118	0.00293	CcSEcCtD
Mianserin—Breast disorder—Epirubicin—testicular cancer	0.00118	0.00291	CcSEcCtD
Mianserin—Hypotension—Cisplatin—testicular cancer	0.00116	0.00288	CcSEcCtD
Mianserin—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.00116	0.0364	CbGpPWpGaD
Mianserin—Confusional state—Etoposide—testicular cancer	0.00115	0.00285	CcSEcCtD
Mianserin—Cardiac arrest—Doxorubicin—testicular cancer	0.00114	0.00284	CcSEcCtD
Mianserin—Pancytopenia—Methotrexate—testicular cancer	0.00114	0.00283	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Cisplatin—testicular cancer	0.00113	0.00281	CcSEcCtD
Mianserin—Asthenia—Dactinomycin—testicular cancer	0.00113	0.0028	CcSEcCtD
Mianserin—HRH2—G alpha (s) signalling events—INSL3—testicular cancer	0.00112	0.0354	CbGpPWpGaD
Mianserin—Neutropenia—Methotrexate—testicular cancer	0.00112	0.00279	CcSEcCtD
Mianserin—Paraesthesia—Cisplatin—testicular cancer	0.00112	0.00277	CcSEcCtD
Mianserin—Thrombocytopenia—Etoposide—testicular cancer	0.00112	0.00277	CcSEcCtD
Mianserin—Tachycardia—Etoposide—testicular cancer	0.00111	0.00276	CcSEcCtD
Mianserin—Skin disorder—Etoposide—testicular cancer	0.00111	0.00275	CcSEcCtD
Mianserin—Erectile dysfunction—Methotrexate—testicular cancer	0.00111	0.00274	CcSEcCtD
Mianserin—CYP2D6—testis—testicular cancer	0.0011	0.00813	CbGeAlD
Mianserin—Breast disorder—Doxorubicin—testicular cancer	0.00109	0.0027	CcSEcCtD
Mianserin—Gastrointestinal disorder—Cisplatin—testicular cancer	0.00107	0.00267	CcSEcCtD
Mianserin—Drowsiness—Methotrexate—testicular cancer	0.00107	0.00266	CcSEcCtD
Mianserin—Pancytopenia—Epirubicin—testicular cancer	0.00107	0.00265	CcSEcCtD
Mianserin—Hypotension—Etoposide—testicular cancer	0.00107	0.00264	CcSEcCtD
Mianserin—Rash—Bleomycin—testicular cancer	0.00107	0.00264	CcSEcCtD
Mianserin—Dermatitis—Bleomycin—testicular cancer	0.00106	0.00264	CcSEcCtD
Mianserin—Neutropenia—Epirubicin—testicular cancer	0.00105	0.00261	CcSEcCtD
Mianserin—HRH1—lymph node—testicular cancer	0.00104	0.00774	CbGeAlD
Mianserin—Asthenia—Ifosfamide—testicular cancer	0.00104	0.00257	CcSEcCtD
Mianserin—Feeling abnormal—Cisplatin—testicular cancer	0.00103	0.00254	CcSEcCtD
Mianserin—ADRA2A—lymph node—testicular cancer	0.00103	0.00761	CbGeAlD
Mianserin—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.00102	0.0323	CbGpPWpGaD
Mianserin—Paraesthesia—Etoposide—testicular cancer	0.00102	0.00254	CcSEcCtD
Mianserin—Weight increased—Epirubicin—testicular cancer	0.00102	0.00254	CcSEcCtD
Mianserin—Pruritus—Ifosfamide—testicular cancer	0.00102	0.00253	CcSEcCtD
Mianserin—Somnolence—Etoposide—testicular cancer	0.00101	0.00251	CcSEcCtD
Mianserin—Hepatobiliary disease—Methotrexate—testicular cancer	0.00101	0.00251	CcSEcCtD
Mianserin—Drowsiness—Epirubicin—testicular cancer	0.001	0.00249	CcSEcCtD
Mianserin—Agranulocytosis—Methotrexate—testicular cancer	0.001	0.00248	CcSEcCtD
Mianserin—Rash—Dactinomycin—testicular cancer	0.000994	0.00246	CcSEcCtD
Mianserin—Pancytopenia—Doxorubicin—testicular cancer	0.000988	0.00245	CcSEcCtD
Mianserin—Gastrointestinal disorder—Etoposide—testicular cancer	0.000985	0.00244	CcSEcCtD
Mianserin—Fatigue—Etoposide—testicular cancer	0.000983	0.00244	CcSEcCtD
Mianserin—Jaundice—Epirubicin—testicular cancer	0.000977	0.00242	CcSEcCtD
Mianserin—Constipation—Etoposide—testicular cancer	0.000975	0.00242	CcSEcCtD
Mianserin—Neutropenia—Doxorubicin—testicular cancer	0.000973	0.00241	CcSEcCtD
Mianserin—SLC6A4—NRF2 pathway—SLC2A6—testicular cancer	0.00097	0.0305	CbGpPWpGaD
Mianserin—Hepatitis—Methotrexate—testicular cancer	0.000962	0.00238	CcSEcCtD
Mianserin—Dizziness—Ifosfamide—testicular cancer	0.000955	0.00237	CcSEcCtD
Mianserin—Hepatobiliary disease—Epirubicin—testicular cancer	0.000948	0.00235	CcSEcCtD
Mianserin—Weight increased—Doxorubicin—testicular cancer	0.000947	0.00235	CcSEcCtD
Mianserin—Feeling abnormal—Etoposide—testicular cancer	0.00094	0.00233	CcSEcCtD
Mianserin—Agranulocytosis—Epirubicin—testicular cancer	0.000935	0.00232	CcSEcCtD
Mianserin—Drowsiness—Doxorubicin—testicular cancer	0.000927	0.0023	CcSEcCtD
Mianserin—Bradycardia—Epirubicin—testicular cancer	0.000916	0.00227	CcSEcCtD
Mianserin—Rash—Ifosfamide—testicular cancer	0.00091	0.00226	CcSEcCtD
Mianserin—Dermatitis—Ifosfamide—testicular cancer	0.00091	0.00226	CcSEcCtD
Mianserin—Jaundice—Doxorubicin—testicular cancer	0.000904	0.00224	CcSEcCtD
Mianserin—Hepatitis—Epirubicin—testicular cancer	0.0009	0.00223	CcSEcCtD
Mianserin—Eye disorder—Methotrexate—testicular cancer	0.000899	0.00223	CcSEcCtD
Mianserin—Tinnitus—Methotrexate—testicular cancer	0.000897	0.00222	CcSEcCtD
Mianserin—Asthenia—Cisplatin—testicular cancer	0.000893	0.00221	CcSEcCtD
Mianserin—Cardiac disorder—Methotrexate—testicular cancer	0.000892	0.00221	CcSEcCtD
Mianserin—Connective tissue disorder—Epirubicin—testicular cancer	0.000884	0.00219	CcSEcCtD
Mianserin—Hepatobiliary disease—Doxorubicin—testicular cancer	0.000877	0.00218	CcSEcCtD
Mianserin—Angiopathy—Methotrexate—testicular cancer	0.000872	0.00216	CcSEcCtD
Mianserin—Mediastinal disorder—Methotrexate—testicular cancer	0.000867	0.00215	CcSEcCtD
Mianserin—Agranulocytosis—Doxorubicin—testicular cancer	0.000866	0.00215	CcSEcCtD
Mianserin—HTR6—G alpha (s) signalling events—INSL3—testicular cancer	0.000862	0.0271	CbGpPWpGaD
Mianserin—HTR7—G alpha (s) signalling events—INSL3—testicular cancer	0.000861	0.0271	CbGpPWpGaD
Mianserin—Bradycardia—Doxorubicin—testicular cancer	0.000848	0.0021	CcSEcCtD
Mianserin—Mental disorder—Methotrexate—testicular cancer	0.000842	0.00209	CcSEcCtD
Mianserin—Eye disorder—Epirubicin—testicular cancer	0.000841	0.00209	CcSEcCtD
Mianserin—Tinnitus—Epirubicin—testicular cancer	0.000839	0.00208	CcSEcCtD
Mianserin—Cardiac disorder—Epirubicin—testicular cancer	0.000835	0.00207	CcSEcCtD
Mianserin—SLC6A2—NRF2 pathway—SLC2A6—testicular cancer	0.000834	0.0263	CbGpPWpGaD
Mianserin—Hepatitis—Doxorubicin—testicular cancer	0.000833	0.00206	CcSEcCtD
Mianserin—Asthenia—Etoposide—testicular cancer	0.000818	0.00203	CcSEcCtD
Mianserin—Connective tissue disorder—Doxorubicin—testicular cancer	0.000818	0.00203	CcSEcCtD
Mianserin—Angiopathy—Epirubicin—testicular cancer	0.000816	0.00202	CcSEcCtD
Mianserin—Mediastinal disorder—Epirubicin—testicular cancer	0.000811	0.00201	CcSEcCtD
Mianserin—Pruritus—Etoposide—testicular cancer	0.000807	0.002	CcSEcCtD
Mianserin—Mental disorder—Epirubicin—testicular cancer	0.000788	0.00195	CcSEcCtD
Mianserin—Rash—Cisplatin—testicular cancer	0.000785	0.00195	CcSEcCtD
Mianserin—Dermatitis—Cisplatin—testicular cancer	0.000784	0.00194	CcSEcCtD
Mianserin—Eye disorder—Doxorubicin—testicular cancer	0.000778	0.00193	CcSEcCtD
Mianserin—Tinnitus—Doxorubicin—testicular cancer	0.000776	0.00193	CcSEcCtD
Mianserin—Anaemia—Methotrexate—testicular cancer	0.000774	0.00192	CcSEcCtD
Mianserin—Cardiac disorder—Doxorubicin—testicular cancer	0.000773	0.00192	CcSEcCtD
Mianserin—Angiopathy—Doxorubicin—testicular cancer	0.000755	0.00187	CcSEcCtD
Mianserin—Dizziness—Etoposide—testicular cancer	0.000754	0.00187	CcSEcCtD
Mianserin—Vertigo—Methotrexate—testicular cancer	0.000752	0.00186	CcSEcCtD
Mianserin—Mediastinal disorder—Doxorubicin—testicular cancer	0.00075	0.00186	CcSEcCtD
Mianserin—Leukopenia—Methotrexate—testicular cancer	0.000749	0.00186	CcSEcCtD
Mianserin—SLC6A3—NRF2 pathway—SLC2A6—testicular cancer	0.000739	0.0233	CbGpPWpGaD
Mianserin—Mental disorder—Doxorubicin—testicular cancer	0.000729	0.00181	CcSEcCtD
Mianserin—Convulsion—Methotrexate—testicular cancer	0.000725	0.0018	CcSEcCtD
Mianserin—Anaemia—Epirubicin—testicular cancer	0.000724	0.0018	CcSEcCtD
Mianserin—Agitation—Epirubicin—testicular cancer	0.00072	0.00179	CcSEcCtD
Mianserin—Rash—Etoposide—testicular cancer	0.000719	0.00178	CcSEcCtD
Mianserin—Dermatitis—Etoposide—testicular cancer	0.000718	0.00178	CcSEcCtD
Mianserin—Headache—Etoposide—testicular cancer	0.000714	0.00177	CcSEcCtD
Mianserin—Myalgia—Methotrexate—testicular cancer	0.000713	0.00177	CcSEcCtD
Mianserin—Arthralgia—Methotrexate—testicular cancer	0.000713	0.00177	CcSEcCtD
Mianserin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000708	0.00176	CcSEcCtD
Mianserin—Vertigo—Epirubicin—testicular cancer	0.000704	0.00175	CcSEcCtD
Mianserin—Syncope—Epirubicin—testicular cancer	0.000702	0.00174	CcSEcCtD
Mianserin—Leukopenia—Epirubicin—testicular cancer	0.000701	0.00174	CcSEcCtD
Mianserin—HRH4—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000691	0.0218	CbGpPWpGaD
Mianserin—Confusional state—Methotrexate—testicular cancer	0.000689	0.00171	CcSEcCtD
Mianserin—Loss of consciousness—Epirubicin—testicular cancer	0.000688	0.00171	CcSEcCtD
Mianserin—Convulsion—Epirubicin—testicular cancer	0.000679	0.00168	CcSEcCtD
Mianserin—Hypertension—Epirubicin—testicular cancer	0.000676	0.00168	CcSEcCtD
Mianserin—Nervous system disorder—Methotrexate—testicular cancer	0.00067	0.00166	CcSEcCtD
Mianserin—Anaemia—Doxorubicin—testicular cancer	0.00067	0.00166	CcSEcCtD
Mianserin—Thrombocytopenia—Methotrexate—testicular cancer	0.000669	0.00166	CcSEcCtD
Mianserin—Arthralgia—Epirubicin—testicular cancer	0.000667	0.00165	CcSEcCtD
Mianserin—Myalgia—Epirubicin—testicular cancer	0.000667	0.00165	CcSEcCtD
Mianserin—Agitation—Doxorubicin—testicular cancer	0.000666	0.00165	CcSEcCtD
Mianserin—Skin disorder—Methotrexate—testicular cancer	0.000664	0.00165	CcSEcCtD
Mianserin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000662	0.00164	CcSEcCtD
Mianserin—Dry mouth—Epirubicin—testicular cancer	0.000652	0.00162	CcSEcCtD
Mianserin—Vertigo—Doxorubicin—testicular cancer	0.000651	0.00161	CcSEcCtD
Mianserin—Syncope—Doxorubicin—testicular cancer	0.00065	0.00161	CcSEcCtD
Mianserin—Leukopenia—Doxorubicin—testicular cancer	0.000649	0.00161	CcSEcCtD
Mianserin—Confusional state—Epirubicin—testicular cancer	0.000645	0.0016	CcSEcCtD
Mianserin—Oedema—Epirubicin—testicular cancer	0.000639	0.00159	CcSEcCtD
Mianserin—Hypotension—Methotrexate—testicular cancer	0.000638	0.00158	CcSEcCtD
Mianserin—HTR1F—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000638	0.0201	CbGpPWpGaD
Mianserin—Loss of consciousness—Doxorubicin—testicular cancer	0.000637	0.00158	CcSEcCtD
Mianserin—Shock—Epirubicin—testicular cancer	0.000629	0.00156	CcSEcCtD
Mianserin—Convulsion—Doxorubicin—testicular cancer	0.000628	0.00156	CcSEcCtD
Mianserin—Nervous system disorder—Epirubicin—testicular cancer	0.000627	0.00155	CcSEcCtD
Mianserin—Thrombocytopenia—Epirubicin—testicular cancer	0.000626	0.00155	CcSEcCtD
Mianserin—Hypertension—Doxorubicin—testicular cancer	0.000626	0.00155	CcSEcCtD
Mianserin—Tachycardia—Epirubicin—testicular cancer	0.000624	0.00155	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000622	0.00154	CcSEcCtD
Mianserin—OPRK1—Peptide ligand-binding receptors—INSL3—testicular cancer	0.000622	0.0196	CbGpPWpGaD
Mianserin—Skin disorder—Epirubicin—testicular cancer	0.000621	0.00154	CcSEcCtD
Mianserin—Myalgia—Doxorubicin—testicular cancer	0.000617	0.00153	CcSEcCtD
Mianserin—Arthralgia—Doxorubicin—testicular cancer	0.000617	0.00153	CcSEcCtD
Mianserin—Paraesthesia—Methotrexate—testicular cancer	0.000613	0.00152	CcSEcCtD
Mianserin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000613	0.00152	CcSEcCtD
Mianserin—Somnolence—Methotrexate—testicular cancer	0.000607	0.00151	CcSEcCtD
Mianserin—Dry mouth—Doxorubicin—testicular cancer	0.000603	0.0015	CcSEcCtD
Mianserin—Hypotension—Epirubicin—testicular cancer	0.000597	0.00148	CcSEcCtD
Mianserin—Confusional state—Doxorubicin—testicular cancer	0.000596	0.00148	CcSEcCtD
Mianserin—Oedema—Doxorubicin—testicular cancer	0.000592	0.00147	CcSEcCtD
Mianserin—Gastrointestinal disorder—Methotrexate—testicular cancer	0.00059	0.00146	CcSEcCtD
Mianserin—Fatigue—Methotrexate—testicular cancer	0.000589	0.00146	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000582	0.00144	CcSEcCtD
Mianserin—Shock—Doxorubicin—testicular cancer	0.000582	0.00144	CcSEcCtD
Mianserin—Nervous system disorder—Doxorubicin—testicular cancer	0.00058	0.00144	CcSEcCtD
Mianserin—Thrombocytopenia—Doxorubicin—testicular cancer	0.000579	0.00144	CcSEcCtD
Mianserin—Tachycardia—Doxorubicin—testicular cancer	0.000577	0.00143	CcSEcCtD
Mianserin—Skin disorder—Doxorubicin—testicular cancer	0.000575	0.00142	CcSEcCtD
Mianserin—Paraesthesia—Epirubicin—testicular cancer	0.000574	0.00142	CcSEcCtD
Mianserin—Somnolence—Epirubicin—testicular cancer	0.000568	0.00141	CcSEcCtD
Mianserin—Feeling abnormal—Methotrexate—testicular cancer	0.000563	0.0014	CcSEcCtD
Mianserin—Hypotension—Doxorubicin—testicular cancer	0.000553	0.00137	CcSEcCtD
Mianserin—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000552	0.00137	CcSEcCtD
Mianserin—Fatigue—Epirubicin—testicular cancer	0.000551	0.00137	CcSEcCtD
Mianserin—Constipation—Epirubicin—testicular cancer	0.000547	0.00136	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000539	0.00134	CcSEcCtD
Mianserin—HRH2—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000536	0.0169	CbGpPWpGaD
Mianserin—Paraesthesia—Doxorubicin—testicular cancer	0.000531	0.00132	CcSEcCtD
Mianserin—Feeling abnormal—Epirubicin—testicular cancer	0.000527	0.00131	CcSEcCtD
Mianserin—HRH4—GPCR ligand binding—INSL3—testicular cancer	0.000526	0.0166	CbGpPWpGaD
Mianserin—Somnolence—Doxorubicin—testicular cancer	0.000526	0.0013	CcSEcCtD
Mianserin—SLC6A2—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000525	0.0166	CbGpPWpGaD
Mianserin—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000511	0.00127	CcSEcCtD
Mianserin—Fatigue—Doxorubicin—testicular cancer	0.00051	0.00126	CcSEcCtD
Mianserin—Constipation—Doxorubicin—testicular cancer	0.000506	0.00125	CcSEcCtD
Mianserin—Asthenia—Methotrexate—testicular cancer	0.00049	0.00122	CcSEcCtD
Mianserin—Feeling abnormal—Doxorubicin—testicular cancer	0.000487	0.00121	CcSEcCtD
Mianserin—HTR1F—GPCR ligand binding—INSL3—testicular cancer	0.000486	0.0153	CbGpPWpGaD
Mianserin—Pruritus—Methotrexate—testicular cancer	0.000483	0.0012	CcSEcCtD
Mianserin—SLC6A3—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000466	0.0147	CbGpPWpGaD
Mianserin—Asthenia—Epirubicin—testicular cancer	0.000459	0.00114	CcSEcCtD
Mianserin—Pruritus—Epirubicin—testicular cancer	0.000452	0.00112	CcSEcCtD
Mianserin—Dizziness—Methotrexate—testicular cancer	0.000452	0.00112	CcSEcCtD
Mianserin—Rash—Methotrexate—testicular cancer	0.000431	0.00107	CcSEcCtD
Mianserin—Dermatitis—Methotrexate—testicular cancer	0.00043	0.00107	CcSEcCtD
Mianserin—Headache—Methotrexate—testicular cancer	0.000428	0.00106	CcSEcCtD
Mianserin—Asthenia—Doxorubicin—testicular cancer	0.000424	0.00105	CcSEcCtD
Mianserin—Dizziness—Epirubicin—testicular cancer	0.000423	0.00105	CcSEcCtD
Mianserin—Pruritus—Doxorubicin—testicular cancer	0.000419	0.00104	CcSEcCtD
Mianserin—OPRK1—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000417	0.0131	CbGpPWpGaD
Mianserin—HTR6—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000411	0.0129	CbGpPWpGaD
Mianserin—HTR7—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.00041	0.0129	CbGpPWpGaD
Mianserin—HRH2—GPCR ligand binding—INSL3—testicular cancer	0.000408	0.0128	CbGpPWpGaD
Mianserin—HTR1D—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000408	0.0128	CbGpPWpGaD
Mianserin—Rash—Epirubicin—testicular cancer	0.000403	0.001	CcSEcCtD
Mianserin—Dermatitis—Epirubicin—testicular cancer	0.000403	0.000999	CcSEcCtD
Mianserin—Headache—Epirubicin—testicular cancer	0.0004	0.000993	CcSEcCtD
Mianserin—Dizziness—Doxorubicin—testicular cancer	0.000391	0.00097	CcSEcCtD
Mianserin—HTR2B—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000375	0.0118	CbGpPWpGaD
Mianserin—Rash—Doxorubicin—testicular cancer	0.000373	0.000925	CcSEcCtD
Mianserin—Dermatitis—Doxorubicin—testicular cancer	0.000373	0.000924	CcSEcCtD
Mianserin—Headache—Doxorubicin—testicular cancer	0.000371	0.000919	CcSEcCtD
Mianserin—DRD3—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000349	0.011	CbGpPWpGaD
Mianserin—OPRK1—GPCR ligand binding—INSL3—testicular cancer	0.000317	0.01	CbGpPWpGaD
Mianserin—ADRA2B—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000315	0.00992	CbGpPWpGaD
Mianserin—HTR6—GPCR ligand binding—INSL3—testicular cancer	0.000313	0.00986	CbGpPWpGaD
Mianserin—HTR7—GPCR ligand binding—INSL3—testicular cancer	0.000313	0.00984	CbGpPWpGaD
Mianserin—HTR1D—GPCR ligand binding—INSL3—testicular cancer	0.00031	0.00978	CbGpPWpGaD
Mianserin—HTR1A—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000304	0.00958	CbGpPWpGaD
Mianserin—HTR2C—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000303	0.00953	CbGpPWpGaD
Mianserin—HRH4—GPCR downstream signaling—INSL3—testicular cancer	0.000297	0.00937	CbGpPWpGaD
Mianserin—ADRA2C—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000294	0.00927	CbGpPWpGaD
Mianserin—HTR2B—GPCR ligand binding—INSL3—testicular cancer	0.000286	0.009	CbGpPWpGaD
Mianserin—HTR1F—GPCR downstream signaling—INSL3—testicular cancer	0.000274	0.00864	CbGpPWpGaD
Mianserin—HRH4—Signaling by GPCR—INSL3—testicular cancer	0.00027	0.0085	CbGpPWpGaD
Mianserin—CYP1A2—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	0.000268	0.00844	CbGpPWpGaD
Mianserin—SLC6A2—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000267	0.00841	CbGpPWpGaD
Mianserin—DRD2—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000267	0.00841	CbGpPWpGaD
Mianserin—DRD3—GPCR ligand binding—INSL3—testicular cancer	0.000266	0.00837	CbGpPWpGaD
Mianserin—HTR2A—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000263	0.00828	CbGpPWpGaD
Mianserin—HRH1—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000262	0.00826	CbGpPWpGaD
Mianserin—CYP1A2—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000251	0.0079	CbGpPWpGaD
Mianserin—HTR1F—Signaling by GPCR—INSL3—testicular cancer	0.000249	0.00785	CbGpPWpGaD
Mianserin—ADRA2B—GPCR ligand binding—INSL3—testicular cancer	0.00024	0.00756	CbGpPWpGaD
Mianserin—ADRA2A—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000239	0.00753	CbGpPWpGaD
Mianserin—SLC6A3—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000237	0.00745	CbGpPWpGaD
Mianserin—HTR1A—GPCR ligand binding—INSL3—testicular cancer	0.000232	0.0073	CbGpPWpGaD
Mianserin—HRH2—GPCR downstream signaling—INSL3—testicular cancer	0.000231	0.00726	CbGpPWpGaD
Mianserin—HTR2C—GPCR ligand binding—INSL3—testicular cancer	0.00023	0.00726	CbGpPWpGaD
Mianserin—ADRA2C—Integration of energy metabolism—STK11—testicular cancer	0.000226	0.00712	CbGpPWpGaD
Mianserin—ADRA2C—GPCR ligand binding—INSL3—testicular cancer	0.000224	0.00706	CbGpPWpGaD
Mianserin—HRH2—Signaling by GPCR—INSL3—testicular cancer	0.000209	0.00659	CbGpPWpGaD
Mianserin—DRD2—GPCR ligand binding—INSL3—testicular cancer	0.000203	0.00641	CbGpPWpGaD
Mianserin—HTR2A—GPCR ligand binding—INSL3—testicular cancer	0.0002	0.0063	CbGpPWpGaD
Mianserin—HRH1—GPCR ligand binding—INSL3—testicular cancer	0.0002	0.00629	CbGpPWpGaD
Mianserin—ADRA2A—Integration of energy metabolism—STK11—testicular cancer	0.000184	0.00579	CbGpPWpGaD
Mianserin—ADRA2A—GPCR ligand binding—INSL3—testicular cancer	0.000182	0.00573	CbGpPWpGaD
Mianserin—OPRK1—GPCR downstream signaling—INSL3—testicular cancer	0.000179	0.00565	CbGpPWpGaD
Mianserin—HTR6—GPCR downstream signaling—INSL3—testicular cancer	0.000177	0.00557	CbGpPWpGaD
Mianserin—HTR7—GPCR downstream signaling—INSL3—testicular cancer	0.000177	0.00556	CbGpPWpGaD
Mianserin—HTR1D—GPCR downstream signaling—INSL3—testicular cancer	0.000175	0.00553	CbGpPWpGaD
Mianserin—OPRK1—Signaling by GPCR—INSL3—testicular cancer	0.000163	0.00513	CbGpPWpGaD
Mianserin—HTR2B—GPCR downstream signaling—INSL3—testicular cancer	0.000161	0.00508	CbGpPWpGaD
Mianserin—HTR6—Signaling by GPCR—INSL3—testicular cancer	0.000161	0.00506	CbGpPWpGaD
Mianserin—HTR7—Signaling by GPCR—INSL3—testicular cancer	0.00016	0.00505	CbGpPWpGaD
Mianserin—CYP1A2—Phase II conjugation—HPGDS—testicular cancer	0.00016	0.00502	CbGpPWpGaD
Mianserin—HRH4—Signaling Pathways—INSL3—testicular cancer	0.000159	0.00502	CbGpPWpGaD
Mianserin—HTR1D—Signaling by GPCR—INSL3—testicular cancer	0.000159	0.00502	CbGpPWpGaD
Mianserin—CYP2B6—Biological oxidations—HPGDS—testicular cancer	0.000158	0.00499	CbGpPWpGaD
Mianserin—DRD3—GPCR downstream signaling—INSL3—testicular cancer	0.00015	0.00473	CbGpPWpGaD
Mianserin—HTR1F—Signaling Pathways—INSL3—testicular cancer	0.000147	0.00464	CbGpPWpGaD
Mianserin—HTR2B—Signaling by GPCR—INSL3—testicular cancer	0.000147	0.00462	CbGpPWpGaD
Mianserin—DRD3—Signaling by GPCR—INSL3—testicular cancer	0.000136	0.0043	CbGpPWpGaD
Mianserin—ADRA2B—GPCR downstream signaling—INSL3—testicular cancer	0.000136	0.00427	CbGpPWpGaD
Mianserin—HTR1A—GPCR downstream signaling—INSL3—testicular cancer	0.000131	0.00412	CbGpPWpGaD
Mianserin—HTR2C—GPCR downstream signaling—INSL3—testicular cancer	0.00013	0.0041	CbGpPWpGaD
Mianserin—ADRA2C—GPCR downstream signaling—INSL3—testicular cancer	0.000127	0.00399	CbGpPWpGaD
Mianserin—HRH2—Signaling Pathways—INSL3—testicular cancer	0.000124	0.0039	CbGpPWpGaD
Mianserin—ADRA2B—Signaling by GPCR—INSL3—testicular cancer	0.000123	0.00388	CbGpPWpGaD
Mianserin—HTR1A—Signaling by GPCR—INSL3—testicular cancer	0.000119	0.00374	CbGpPWpGaD
Mianserin—HTR2C—Signaling by GPCR—INSL3—testicular cancer	0.000118	0.00372	CbGpPWpGaD
Mianserin—ADRA2C—Signaling by GPCR—INSL3—testicular cancer	0.000115	0.00362	CbGpPWpGaD
Mianserin—DRD2—GPCR downstream signaling—INSL3—testicular cancer	0.000115	0.00362	CbGpPWpGaD
Mianserin—HTR2A—GPCR downstream signaling—INSL3—testicular cancer	0.000113	0.00356	CbGpPWpGaD
Mianserin—HRH1—GPCR downstream signaling—INSL3—testicular cancer	0.000113	0.00355	CbGpPWpGaD
Mianserin—CYP2D6—Biological oxidations—HPGDS—testicular cancer	0.00011	0.00347	CbGpPWpGaD
Mianserin—DRD2—Signaling by GPCR—INSL3—testicular cancer	0.000104	0.00329	CbGpPWpGaD
Mianserin—ADRA2A—GPCR downstream signaling—INSL3—testicular cancer	0.000103	0.00324	CbGpPWpGaD
Mianserin—HTR2A—Signaling by GPCR—INSL3—testicular cancer	0.000103	0.00323	CbGpPWpGaD
Mianserin—HRH1—Signaling by GPCR—INSL3—testicular cancer	0.000102	0.00323	CbGpPWpGaD
Mianserin—OPRK1—Signaling Pathways—INSL3—testicular cancer	9.62e-05	0.00303	CbGpPWpGaD
Mianserin—HTR6—Signaling Pathways—INSL3—testicular cancer	9.49e-05	0.00299	CbGpPWpGaD
Mianserin—HTR7—Signaling Pathways—INSL3—testicular cancer	9.47e-05	0.00298	CbGpPWpGaD
Mianserin—HTR1D—Signaling Pathways—INSL3—testicular cancer	9.41e-05	0.00296	CbGpPWpGaD
Mianserin—ADRA2A—Signaling by GPCR—INSL3—testicular cancer	9.34e-05	0.00294	CbGpPWpGaD
Mianserin—CYP1A2—Biological oxidations—HPGDS—testicular cancer	9.33e-05	0.00294	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—INSL3—testicular cancer	8.66e-05	0.00273	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—INSL3—testicular cancer	8.06e-05	0.00254	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—INSL3—testicular cancer	7.27e-05	0.00229	CbGpPWpGaD
Mianserin—CYP3A4—Biological oxidations—HPGDS—testicular cancer	7.2e-05	0.00227	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—INSL3—testicular cancer	7.02e-05	0.00221	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—INSL3—testicular cancer	6.99e-05	0.0022	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—INSL3—testicular cancer	6.79e-05	0.00214	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—INSL3—testicular cancer	6.16e-05	0.00194	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—INSL3—testicular cancer	6.07e-05	0.00191	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—INSL3—testicular cancer	6.05e-05	0.00191	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—INSL3—testicular cancer	5.52e-05	0.00174	CbGpPWpGaD
Mianserin—HRH4—Signaling Pathways—H2AFZ—testicular cancer	5.11e-05	0.00161	CbGpPWpGaD
Mianserin—HRH4—Signaling Pathways—STK11—testicular cancer	5.08e-05	0.0016	CbGpPWpGaD
Mianserin—HTR1F—Signaling Pathways—H2AFZ—testicular cancer	4.71e-05	0.00148	CbGpPWpGaD
Mianserin—HRH4—Signaling Pathways—KITLG—testicular cancer	4.7e-05	0.00148	CbGpPWpGaD
Mianserin—HTR1F—Signaling Pathways—STK11—testicular cancer	4.68e-05	0.00148	CbGpPWpGaD
Mianserin—HTR1F—Signaling Pathways—KITLG—testicular cancer	4.33e-05	0.00137	CbGpPWpGaD
Mianserin—HRH2—Signaling Pathways—H2AFZ—testicular cancer	3.96e-05	0.00125	CbGpPWpGaD
Mianserin—HRH2—Signaling Pathways—STK11—testicular cancer	3.94e-05	0.00124	CbGpPWpGaD
Mianserin—HRH2—Signaling Pathways—KITLG—testicular cancer	3.64e-05	0.00115	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	3.58e-05	0.00113	CbGpPWpGaD
Mianserin—ADRA2C—Metabolism—HPGDS—testicular cancer	3.56e-05	0.00112	CbGpPWpGaD
Mianserin—HRH4—Signaling Pathways—FGFR3—testicular cancer	3.49e-05	0.0011	CbGpPWpGaD
Mianserin—HTR1F—Signaling Pathways—FGFR3—testicular cancer	3.22e-05	0.00101	CbGpPWpGaD
Mianserin—HRH4—Signaling Pathways—KIT—testicular cancer	3.2e-05	0.00101	CbGpPWpGaD
Mianserin—OPRK1—Signaling Pathways—H2AFZ—testicular cancer	3.08e-05	0.00097	CbGpPWpGaD
Mianserin—OPRK1—Signaling Pathways—STK11—testicular cancer	3.06e-05	0.000965	CbGpPWpGaD
Mianserin—HTR6—Signaling Pathways—H2AFZ—testicular cancer	3.04e-05	0.000956	CbGpPWpGaD
Mianserin—HTR7—Signaling Pathways—H2AFZ—testicular cancer	3.03e-05	0.000955	CbGpPWpGaD
Mianserin—HTR6—Signaling Pathways—STK11—testicular cancer	3.02e-05	0.000951	CbGpPWpGaD
Mianserin—HTR7—Signaling Pathways—STK11—testicular cancer	3.02e-05	0.00095	CbGpPWpGaD
Mianserin—HTR1D—Signaling Pathways—H2AFZ—testicular cancer	3.01e-05	0.000949	CbGpPWpGaD
Mianserin—HTR1D—Signaling Pathways—STK11—testicular cancer	3e-05	0.000944	CbGpPWpGaD
Mianserin—HTR1F—Signaling Pathways—KIT—testicular cancer	2.96e-05	0.000932	CbGpPWpGaD
Mianserin—ADRA2A—Metabolism—HPGDS—testicular cancer	2.89e-05	0.000911	CbGpPWpGaD
Mianserin—OPRK1—Signaling Pathways—KITLG—testicular cancer	2.83e-05	0.000893	CbGpPWpGaD
Mianserin—HTR6—Signaling Pathways—KITLG—testicular cancer	2.79e-05	0.00088	CbGpPWpGaD
Mianserin—HTR7—Signaling Pathways—KITLG—testicular cancer	2.79e-05	0.000879	CbGpPWpGaD
Mianserin—HTR1D—Signaling Pathways—KITLG—testicular cancer	2.77e-05	0.000873	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—H2AFZ—testicular cancer	2.77e-05	0.000873	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—STK11—testicular cancer	2.76e-05	0.000868	CbGpPWpGaD
Mianserin—CYP2B6—Metabolism—HPGDS—testicular cancer	2.71e-05	0.000854	CbGpPWpGaD
Mianserin—HRH2—Signaling Pathways—FGFR3—testicular cancer	2.71e-05	0.000853	CbGpPWpGaD
Mianserin—ADRA2C—Metabolism—STK11—testicular cancer	2.59e-05	0.000815	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—H2AFZ—testicular cancer	2.58e-05	0.000812	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—STK11—testicular cancer	2.56e-05	0.000808	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—KITLG—testicular cancer	2.55e-05	0.000803	CbGpPWpGaD
Mianserin—HRH2—Signaling Pathways—KIT—testicular cancer	2.49e-05	0.000783	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—KITLG—testicular cancer	2.37e-05	0.000747	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—H2AFZ—testicular cancer	2.33e-05	0.000733	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—STK11—testicular cancer	2.31e-05	0.000729	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—H2AFZ—testicular cancer	2.25e-05	0.000708	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—H2AFZ—testicular cancer	2.24e-05	0.000704	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—STK11—testicular cancer	2.23e-05	0.000704	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—STK11—testicular cancer	2.22e-05	0.0007	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—H2AFZ—testicular cancer	2.17e-05	0.000685	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—STK11—testicular cancer	2.16e-05	0.000681	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—KITLG—testicular cancer	2.14e-05	0.000675	CbGpPWpGaD
Mianserin—OPRK1—Signaling Pathways—FGFR3—testicular cancer	2.11e-05	0.000663	CbGpPWpGaD
Mianserin—ADRA2A—Metabolism—STK11—testicular cancer	2.1e-05	0.000662	CbGpPWpGaD
Mianserin—HTR6—Signaling Pathways—FGFR3—testicular cancer	2.08e-05	0.000654	CbGpPWpGaD
Mianserin—HTR7—Signaling Pathways—FGFR3—testicular cancer	2.07e-05	0.000653	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—KITLG—testicular cancer	2.07e-05	0.000651	CbGpPWpGaD
Mianserin—HTR1D—Signaling Pathways—FGFR3—testicular cancer	2.06e-05	0.000649	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—KITLG—testicular cancer	2.06e-05	0.000648	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—KITLG—testicular cancer	2e-05	0.00063	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—H2AFZ—testicular cancer	1.97e-05	0.000622	CbGpPWpGaD
Mianserin—CYP2B6—Metabolism—STK11—testicular cancer	1.97e-05	0.00062	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—STK11—testicular cancer	1.96e-05	0.000618	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—H2AFZ—testicular cancer	1.94e-05	0.000612	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—H2AFZ—testicular cancer	1.94e-05	0.00061	CbGpPWpGaD
Mianserin—OPRK1—Signaling Pathways—KIT—testicular cancer	1.93e-05	0.000609	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—STK11—testicular cancer	1.93e-05	0.000608	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—STK11—testicular cancer	1.93e-05	0.000607	CbGpPWpGaD
Mianserin—HTR6—Signaling Pathways—KIT—testicular cancer	1.91e-05	0.0006	CbGpPWpGaD
Mianserin—HTR7—Signaling Pathways—KIT—testicular cancer	1.9e-05	0.0006	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—FGFR3—testicular cancer	1.89e-05	0.000597	CbGpPWpGaD
Mianserin—HTR1D—Signaling Pathways—KIT—testicular cancer	1.89e-05	0.000596	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—HPGDS—testicular cancer	1.88e-05	0.000593	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—KITLG—testicular cancer	1.82e-05	0.000572	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—KITLG—testicular cancer	1.79e-05	0.000563	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—KITLG—testicular cancer	1.78e-05	0.000561	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—H2AFZ—testicular cancer	1.77e-05	0.000556	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—FGFR3—testicular cancer	1.76e-05	0.000555	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—STK11—testicular cancer	1.76e-05	0.000553	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—KIT—testicular cancer	1.74e-05	0.000548	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—KITLG—testicular cancer	1.63e-05	0.000512	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—KIT—testicular cancer	1.62e-05	0.00051	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—HPGDS—testicular cancer	1.6e-05	0.000503	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—FGFR3—testicular cancer	1.59e-05	0.000501	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—FGFR3—testicular cancer	1.54e-05	0.000484	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—FGFR3—testicular cancer	1.53e-05	0.000482	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—FGFR3—testicular cancer	1.49e-05	0.000468	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—KIT—testicular cancer	1.46e-05	0.00046	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—KIT—testicular cancer	1.41e-05	0.000444	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—KIT—testicular cancer	1.4e-05	0.000442	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—STK11—testicular cancer	1.37e-05	0.000431	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—KIT—testicular cancer	1.37e-05	0.00043	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—FGFR3—testicular cancer	1.35e-05	0.000425	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—FGFR3—testicular cancer	1.33e-05	0.000418	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—FGFR3—testicular cancer	1.32e-05	0.000417	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—KIT—testicular cancer	1.24e-05	0.00039	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—HPGDS—testicular cancer	1.23e-05	0.000388	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—KIT—testicular cancer	1.22e-05	0.000384	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—KIT—testicular cancer	1.22e-05	0.000383	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—FGFR3—testicular cancer	1.21e-05	0.00038	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—STK11—testicular cancer	1.16e-05	0.000365	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—KIT—testicular cancer	1.11e-05	0.000349	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—STK11—testicular cancer	8.95e-06	0.000282	CbGpPWpGaD
